Excerpt · Washington Examiner
The Food and Drug Administration on Wednesday rubber-stamped a new drug to treat pancreatic cancer and substantially extend the lives of patients. The drug, daraxonrasib, is produced by Revolution Medicines and was approved for individuals with metastatic pancreatic cancer who did not see success with chemotherapy.…
We haven't published a neutral rewrite of this one, so we don't reproduce the original in full — the reporting belongs to Washington Examiner. You can still compare how outlets framed this story below.